Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indaptus Therapeutics ( (INDP) ) has provided an announcement.
Indaptus Therapeutics held its Annual Meeting on June 10, 2025, where shareholders voted on several key proposals. The election of three Class I directors, the ratification of Haskell & White LLP as the independent accounting firm, the approval of executive compensation, and an amendment for a reverse stock split were all approved, indicating strong shareholder support for the company’s strategic decisions.
The most recent analyst rating on (INDP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.
Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Average Trading Volume: 714,543
Technical Sentiment Signal: Sell
Current Market Cap: $5.28M
See more data about INDP stock on TipRanks’ Stock Analysis page.